Eli Lilly and Company $LLY Shares Sold by Simplicity Wealth LLC

Simplicity Wealth LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 36.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,822 shares of the company’s stock after selling 4,466 shares during the quarter. Simplicity Wealth LLC’s holdings in Eli Lilly and Company were worth $5,968,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Laurel Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares in the last quarter. Norges Bank purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $8,827,714,000. Vanguard Group Inc. boosted its stake in Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after purchasing an additional 1,183,038 shares during the period. Franklin Resources Inc. grew its position in Eli Lilly and Company by 13.4% during the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after purchasing an additional 564,736 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its stake in Eli Lilly and Company by 87.2% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,152,281 shares of the company’s stock valued at $898,238,000 after purchasing an additional 536,679 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on LLY. Deutsche Bank Aktiengesellschaft raised their target price on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. National Bankshares set a $1,286.00 price target on shares of Eli Lilly and Company in a report on Monday, December 1st. Leerink Partners set a $1,234.00 price objective on shares of Eli Lilly and Company in a research note on Monday, January 5th. Finally, Berenberg Bank increased their target price on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research report on Tuesday, December 2nd. Four analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $1,174.61.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA grants Breakthrough Therapy designation to Lilly’s ovarian-cancer candidate sofetabart (mipitecan), accelerating regulator engagement and potentially speeding development for a high‑need oncology indication. FDA Grants Breakthrough Therapy Tag to LLY’s Ovarian Cancer Candidate
• Positive Sentiment: Lilly announces SURMOUNT-REAL UK, a phase 4 real-world study of tirzepatide (obesity), which, if supportive, could broaden real‑world uptake and long‑term market potential for its GLP‑1 franchise. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: Retatrutide trial update links weight-loss therapy to potential knee osteoarthritis relief — a signal that obesity drugs may unlock additional labeled uses and payor value. Eli Lilly’s Retatrutide Trial Links Obesity Treatment With Knee Osteoarthritis Relief Potential
• Positive Sentiment: Lilly opens a phase 2 trial for a new oral pain candidate targeting diabetic nerve pain, expanding its non‑GLP-1 pipeline and future revenue diversification. Eli Lilly Expands Its Pain Pipeline With New Phase 2 Trial in Diabetic Nerve Pain
• Positive Sentiment: Market commentary and analyst previews (Seeking Alpha, MarketBeat, Zacks) are bullish ahead of earnings, highlighting Mounjaro/Zepbound sales and pipeline catalysts as drivers for higher valuations. Eli Lilly: Buy Ahead Of Its Earnings Day (Preview)
• Neutral Sentiment: Lilly confirmed its Q4 2025 results and conference call for Feb. 4, 2026 — a near-term liquidity/event date that will likely set the next major directional cue. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Guggenheim slightly trimmed its price target (from $1,163 to $1,161) but kept a buy rating — a marginal analyst tweak that is unlikely to materially change the investment thesis. LLY price target lowered by Guggenheim
• Neutral Sentiment: Rumors about a potential Abivax takeover involving Lilly were downplayed by Abivax’s CEO, reducing speculative takeover chatter. Abivax CEO Dismisses Rumors of Eli Lilly Takeover
• Negative Sentiment: A Seeking Alpha piece on Novo Nordisk’s new CEO frames a potential intensifying rivalry; stronger competition from Novo could pressure Lilly’s longer-term market share in GLP‑1 products. Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026

Eli Lilly and Company Trading Up 3.6%

NYSE:LLY opened at $1,078.98 on Thursday. The company’s 50 day moving average is $1,055.07 and its 200-day moving average is $876.57. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The firm has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.79, a P/E/G ratio of 0.78 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the business posted $1.18 EPS. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.